Asymmetric dimethylarginine (ADMA) is a toxic, non-proteinogenic amino acid formed by post-translational modification. It is a uremic toxin that inhibits the production of nitric oxide (NO) and plays a role in many human diseases. ADMA has become a predictor of cardiovascular disease, metabolic syndrome and a range of disease. Creative BioMart Biomarker is capable to provide our customers with superior ADMA detection service, various detection methods ensuring high sensitivity for detecting biomarkers in different samples with different concentrations.
Introduction
ADMA was first isolated from human urine in 1970. Among the guanidine compounds considered to be uremic toxins, ADMA has been recognized as a toxic non-proteinogenic amino acid in various human diseases. ADMA is an endogenous inhibitor of nitric oxide synthase that causes vasoconstriction and restrict blood flow, resulting in elevated blood pressure in the body. Patients with renal insufficiency, diabetes and metabolic syndrome have elevated plasma ADMA levels.
Several studies have demonstrated the relationship between high ADMA concentrations and cardiovascular disease. Elevated levels of ADMA are prevalent in hypercholesterolemia, hyperhomocysteinemia, diabetes mellitus, peripheral arterial occlusive disease, hypertension, chronic heart failure, and coronary artery disease. These studies were case-control studies and were unable to determine the causa-effect relationship between ADMA and cardiovascular disease. However, subsequent observations revealed elevated levels of ADMA in the early stages of atherosclerosis, suggesting that ADMA is not only a marker of vascular disease but also a mediator of vascular disease. To date, several studies have used serum and plasma ADMA as a new cardiovascular risk factor.
Application of ADMA
Plasma, serum levels of ADMA, can be used as a predictor of cardiovascular disease, metabolic syndrome and a range of disease.
Our Advantages
- Accept a wide range of sample types
- Provide multiple detection methods
- Ensure high sensitivity for detecting ADMA in different samples
- Ensure high accuracy and repeatable ADMA detection
- Ensure a wide kinetic range to detect samples of different concentrations
- Short experimental period
Workflow of ADMA Detection at Creative BioMart Biomarker
Creative BioMart Biomarker strictly controls each specific experimental step in the ADMA detection procedure to ensure high sensitivity, high accuracy and repeatable ADMA detection.
Please feel free to contact us if you would like to know more about ADMA detection. At Creative BioMart Biomarker, we not only provide high-quality ADMA detection service, but also provide detection services for other biomarkers. Additionally, our experts can also provide and help design the best solution according to your specific requirements.
References:
- Tain, Y.L.; Hsu, C.N. Toxic dimethylarginines: asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). Toxins.2017, 9(3).
- Yamamoto, R.; Aso, Y. Synergistic association of metabolic syndrome and overt nephropathy with elevated asymmetric dimethylarginine in serum and impaired cutaneous microvasodilation in patients with type 2 diabetes. Diabetes Care. 2006, 29(4): 928-930.
- Saigusa, D.; et al. Determination of asymmetric dimethylarginine and symmetric dimethylarginine in biological samples of mice using LC/MS/MS. American Journal of Analytical Chemistry. 2011, 2(03):303-313.
- Böger, R.H. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med. 2005, 1: S19-25.
